44 search results for: chronic inflammation

Event Page Thumbnail
Congress
27
April
2026
Congress
ADVENT at CEORL-HNS 2026

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

2025 ADVENT Forum | Potential for Disease Modification in the Airway
Type 2 Inflammation
2025 ADVENT Forum | Potential for Disease Modification in the Airway
expert video

Unlock new perspectives on managing chronic airway diseases. Profs. Leonard Bacharier, Eugenio De Corso, Stella Lee, Marc Miravitlles, Celeste Porsbjerg, Klaus Rabe, and Martin Wagenmann – share their collective wisdom and experience on the evolving landscape of therapeutic strategies aimed at truly modifying disease progression, offering renewed hope for patients and practitioners alike.

View more
ADVENT at ATS 2026
On Demand
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

2025 ADVENT Forum | Remodeling in the Airway: A Damaged State of Affairs
Type 2 Inflammation
2025 ADVENT Forum | Remodeling in the Airway: A Damaged State of Affairs
expert video

Explore the intricate world of airway remodeling with this comprehensive recording of the live session held at the 2025 ADVENT Forum: "Remodeling in the Airway: A Damaged State of Affairs." Moderated by Dr. Stella Lee, this session brings together a powerhouse multidisciplinary panel to dissect the multifaceted nature of airway damage.

View more
thumbnail
Congress
19
October
2026
Congress
ADVENT at CHEST 2026

At CHEST 2026, the Sanofi & Regeneron ADVENT Booth #833 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
On Demand
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

The Role of IL-4 and IL-13 in CSU Pathogenesis
Type 2 Inflammation
The Role of IL-4 and IL-13 in CSU Pathogenesis
interactivity

Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.

View more
ERS 2026
Congress
5
September
2026
Congress
ADVENT at ERS 2026

Join Sanofi and Regeneron for four educational symposia on asthma, COPD, and the unified airway.

Understanding the Full Scope of PN: Lesions, Dyspigmentation, and Patient Burden
Dermatology
Understanding the Full Scope of PN: Lesions, Dyspigmentation, and Patient Burden
expert video

Professor Matthias Augustin details the various clinical manifestations of prurigo nodularis, illustrating how different lesion types can present concurrently in patients.

View more
World Anosmia Day 2026
On Demand
World Anosmia Day 2026

Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

.
Congress
9
March
2024
Congress
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

UEG Upcoming Events Carousel Thumbnail
Congress
5
October
2025
Congress
ADVENT at UEG WEEK 2025 | Bridging the Gap in EoE: Innovative Strategies for Seamless Transition of Care

Join Thomas Greuter, MD, Edoardo Vincenzo Savarino, MD, PhD, and Carla Giordano, MD, PhD, for an educational symposium as they use a case-based approach to explore the impact of chronic type 2 inflammation in EoE and outline strategies for optimizing transition of care and monitoring disease progression.